Werewolf Therapeutics Past Earnings Performance
Past criteria checks 0/6
Werewolf Therapeutics has been growing earnings at an average annual rate of 20.9%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been growing at an average rate of 89.2% per year.
Key information
20.9%
Earnings growth rate
83.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 89.2% |
| Return on equity | -35.4% |
| Net Margin | -256.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding
Jun 04
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Apr 04Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Feb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise
Dec 09Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates
Sep 30Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 13We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Dec 09Revenue & Expenses Breakdown
How Werewolf Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 16 | -42 | 22 | 0 |
| 31 Dec 23 | 20 | -37 | 22 | 0 |
| 30 Sep 23 | 26 | -37 | 21 | 0 |
| 30 Jun 23 | 25 | -41 | 21 | 0 |
| 31 Mar 23 | 21 | -50 | 22 | 0 |
| 31 Dec 22 | 16 | -54 | 22 | 0 |
| 30 Sep 22 | 9 | -60 | 20 | 0 |
| 30 Jun 22 | 4 | -62 | 19 | 0 |
| 31 Mar 22 | 0 | -115 | 18 | 0 |
| 31 Dec 21 | 0 | -202 | 16 | 0 |
| 30 Sep 21 | 0 | -205 | 12 | 5 |
| 30 Jun 21 | 0 | -197 | 10 | 10 |
| 31 Mar 21 | 0 | -127 | 7 | 14 |
| 31 Dec 20 | 0 | -28 | 6 | 17 |
Quality Earnings: HOWL is currently unprofitable.
Growing Profit Margin: HOWL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HOWL is unprofitable, but has reduced losses over the past 5 years at a rate of 20.9% per year.
Accelerating Growth: Unable to compare HOWL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HOWL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: HOWL has a negative Return on Equity (-35.36%), as it is currently unprofitable.